Navigation Links
Life Technologies Announces Regulatory Approval of 3500 Dx Series Genetic Analyzers in Mexico

CARLSBAD, Calif., May 20, 2013 /PRNewswire/ -- Life Technologies Corporation (NASDAQ: LIFE) today announced that its Applied Biosystems™ 3500 Dx and 3500xL Dx Genetic Analyzers have been approved by the Federal Commission for Protection against Health Risks in Mexico for diagnostic use.  The development marks a major extension of Life Technologies' capabilities to serve the clinical end market in North America with Sanger-based solutions. 

The Applied Biosystems™ 3500 Dx Series Genetic Analyzers deliver high quality performance, higher throughput and increased productivity for clinical laboratories around the world. The 3500xL Dx is an automated 24 capillary-based Sanger Sequencer; the 3500 Dx is an eight capillary instrument. Together, the offering of both 3500 Dx and 3500xL Dx provides hospitals of all sizes the flexibility they need to meet their unique throughput demands designed for a wide range of sequencing applications. In addition to diagnostic use, the instruments are appropriate for a wide range of research applications, including de novo sequencing and mutational profiling.  

"The current approval of the 3500 Dx Series Genetic Analyzers emphasizes Life Technologies' success in pursuing regulatory pathways for our diagnostics laboratory instruments, as well as our vision to becoming a global leader in the molecular diagnostics industry," said Ronnie Andrews , president of Medical Sciences at Life Technologies.

Applied Biosystems Sanger Sequencers supplied the technology that powered the Human Genome Project, and Sanger instruments remain the sequencing "gold-standard" for accuracy, reliability and ease of use. The participation of the sequencing technologies in clinical diagnostics is reshaping the disease treatment paradigm worldwide.     

Additional products offered by Life Technologies for the molecular diagnostics lab market in Mexico include the Applied Biosystems™ 7500 Fast Dx Real-time PCR instrument, approved for diagnostic use by the Federal Commission for Protection against Health Risks in Mexico in January, 2013.

About Life Technologies 
Life Technologies Corporation (NASDAQ:  LIFE) is a global biotechnology company that is committed to providing the most innovative products and services to leading customers in the fields of scientific research, genetic analysis and applied sciences. With a presence in more than 180 countries, the company's portfolio of 50,000 end-to-end solutions is secured by more than 5,000 patents and licenses that span the entire biological spectrum -- scientific exploration, molecular diagnostics, 21st century forensics, regenerative medicine and agricultural research. Life Technologies has approximately 10,000 employees and had sales of $3.8 billion in 2012.

Life Technologies' Safe Harbor Statement
This press release includes forward-looking statements about Life Technologies' anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies' plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.


Life Technologies Contact
Suzanne Clancy
858-205-4235 (mobile)

SOURCE Life Technologies Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmaceutical Makers and Delivery Device Partners Rethink Delivery Technologies - New Report Examines this Evolving Segment
2. MultiCell Technologies Files U.S. Patent Application for Targeted Delivery of Noncoding Micro RNAs for the Treatment of Liver Cancer
3. Immunoassays: Technologies and Global Markets -- Focus on Infectious Disease Immunoassays
4. PharmaSphere: Early-Stage Technology Transfer Collaborations - Enabling Platform Technologies & Deal Synergies between Academia and the Pharmaceutical Industry
5. AG Mednet CEO Abraham Gutman to Moderate Disruptive Technologies Session at CenterWatch Forum on Optimizing Clinical Research Performance
6. Patient Safety Technologies Reports First Quarter 2013 Results
7. Patent Protection for TAL Effector Technology Enables Licensing Path for Life Technologies Customers
8. BioSpecifics Technologies Corp. to Host Conference Call to Report First Quarter 2013 Financial Results on Friday, May 10, 2013
9. Blue Belt Technologies kündigt Gründung eines wissenschaftlichen Beirats für Hüfteingriffe zur Bestimmung neuer Anwendungsgebiete von NavioPFS bei femoro-acetabulärem Impingement an
10. Blue Belt Technologies maakt vorming van Wetenschappelijke Heup Adviesraad bekend voor ontwikkeling van volgende NavioPFS-toepassing voor femoroacetabulair impingement
11. Blue Belt Technologies Announces Formation of Hip Scientific Advisory Board for Development of Next NavioPFS Application for Femoroacetabular Impingement
Post Your Comments:
(Date:11/24/2015)... 2015 Abaxis, Inc. (NasdaqGS: ABAX ), ... for the medical, research, and veterinary markets worldwide, announced ... will present at the 27 th Annual Piper ... 11:30 a.m. ET. The conference will be held at ... York City . Abaxis, Inc. is ...
(Date:11/24/2015)... , Nov. 24, 2015  Eyewear brand Revo ... with U2 lead singer and activist Bono as part of ... vision impairment and blindness in more than 5 million people ... Revo will donate $10 from the sale of every pair ... to a total of $10 million to the "Buy Vision, ...
(Date:11/24/2015)... , Nov. 24, 2015   Mast Therapeutics, Inc. ... its molecular adhesion and sealant technology (MAST) platform to ... and stroke, today announced that the Company,s Chief Executive ... the Piper Jaffray 27 th Annual Healthcare Conference ... at the New York Palace hotel in ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... November 24, 2015 , ... In an article ... variables that determine which patients are or are not eligible for bariatric surgery. The ... BMI over 40, are more than 100 pounds overweight, or have a BMI of ...
(Date:11/24/2015)... ... November 24, 2015 , ... It takes only three to five seconds to ... that the first impression be positive and reflects business values. If a client starts ... or want to return. They will also share their thoughts about a business with ...
(Date:11/24/2015)... ... 24, 2015 , ... Cancer patients, survivors, caregivers, family members ... live taping of the next CURE Connections® video series on Saturday, ... Symposium at Georgetown University Hotel & Conference Center in Washington, D.C. , CURE ...
(Date:11/24/2015)... ... November 24, 2015 , ... Aided by seed funding from the Ron Foley ... to yield insights into how to detect and treat pancreatic cancer (PC). , ... small, non-coding RNA molecules (ncRNA), genetic material that is present in the blood of ...
(Date:11/24/2015)... ... 24, 2015 , ... Sir Grout of Baltimore is proud ... The award recognizes good companies for excellence in service and a commitment to ... hard surface restoration company earned this recognition after a thorough review by the ...
Breaking Medicine News(10 mins):